What are the key takeaways from this The Prof G Pod episode?

Key insights include: **US-China Power Shift:** Assess China as the senior geopolitical partner heading into the September 24 summit. The US faces compounding weaknesses: a botched Iran policy, rising Democratic midterm odds, and strained G7 alliances. China's rare earth dominance — 70% of global mining, 90%+ of processing — gives Beijing direct leverage over US weapons manufacturing supply chains.; **SCO as Counter-Western Bloc:** Track the Shanghai Cooperation Organization as a concrete measure of China's alternative global order. The 10-member bloc covers 42% of world population, 36% of GDP by purchasing power parity, and $523 billion in internal trade. It is establishing its own development bank explicitly designed to shield members from Western financial sanctions.; **China Pharma Out-Licensing Surge:** Monitor Chinese pharmaceutical out-licensing deals as a leading indicator of global drug innovation shifts. Deals above $50 million grew from 5% of global share in 2021 to 30% in 2025, reaching 42% in the first half of 2026 alone. AstraZeneca's $18.5 billion deal with CSPC in March 2026 represents the largest single transaction to date.

What did James King and Alice Han discuss on The Prof G Pod?

Hosts Alice Han and James King analyze the September 24 Trump-Xi Washington summit alongside guest Ruby Wong, author of *China Cure*, who details China's pharmaceutical rise — from controlling 50% of global API capacity to generating 42% of major out-licensing deals in the first half of 2026. Key topics include: **US-China Power Shift:** Assess China as the senior geopolitical partner heading into the September 24 summit. The US faces compounding weaknesses: a botched Iran policy, rising Democratic midterm odds, and strained G7 alliances. China's rare earth dominance — 70% of global mining, 90%+ of processing — gives Beijing direct leverage over US weapons manufacturing supply chains.; **SCO as Counter-Western Bloc:** Track the Shanghai Cooperation Organization as a concrete measure of China's alternative global order. The 10-member bloc covers 42% of world population, 36% of GDP by purchasing power parity, and $523 billion in internal trade. It is establishing its own development bank explicitly designed to shield members from Western financial sanctions..

How long is this episode of The Prof G Pod?

This episode is 48 minutes long. SignalCast provides an AI-generated summary so you can get the key insights in about 3 minutes.

The Prof G Pod

China Decode: What's at Stake Ahead of Trump and Xi's September Meeting, and China's Biotech Surge

September 8, 2026

48 min episode · 2 min read

James King,Alice Han

Episode

48 min

Read time

2 min

Topics

Productivity, Relationships, Fundraising & VC

AI-Generated Summary

Published Sep 8, 2026

Key Takeaways

✓US-China Power Shift: Assess China as the senior geopolitical partner heading into the September 24 summit. The US faces compounding weaknesses: a botched Iran policy, rising Democratic midterm odds, and strained G7 alliances. China's rare earth dominance — 70% of global mining, 90%+ of processing — gives Beijing direct leverage over US weapons manufacturing supply chains.
✓SCO as Counter-Western Bloc: Track the Shanghai Cooperation Organization as a concrete measure of China's alternative global order. The 10-member bloc covers 42% of world population, 36% of GDP by purchasing power parity, and $523 billion in internal trade. It is establishing its own development bank explicitly designed to shield members from Western financial sanctions.
✓China Pharma Out-Licensing Surge: Monitor Chinese pharmaceutical out-licensing deals as a leading indicator of global drug innovation shifts. Deals above $50 million grew from 5% of global share in 2021 to 30% in 2025, reaching 42% in the first half of 2026 alone. AstraZeneca's $18.5 billion deal with CSPC in March 2026 represents the largest single transaction to date.
✓Drug Development Cost and Speed Advantage: Factor in China's 30–50% cost reduction and 30–60% faster development timelines when evaluating pharmaceutical partnerships. AI-native companies like In Silico Medicine report 70% reductions in discovery time and evaluated only 78 drug candidates versus the industry norm of thousands, signaling structural efficiency gains beyond simple labor arbitrage.
✓STAR Market Growth Trajectory: Watch China's STAR Market — currently 600 companies at $2.3 trillion combined market cap, skewed toward semiconductors, AI, and robotics — as the primary venue for next-generation Chinese tech listings. Domestic listing incentives are replacing New York and Hong Kong preferences, with the STAR Market potentially surpassing Hong Kong's $6.25 trillion market cap within a decade.

What It Covers

Hosts Alice Han and James King analyze the September 24 Trump-Xi Washington summit alongside guest Ruby Wong, author of *China Cure*, who details China's pharmaceutical rise — from controlling 50% of global API capacity to generating 42% of major out-licensing deals in the first half of 2026.

Key Questions Answered

•US-China Power Shift: Assess China as the senior geopolitical partner heading into the September 24 summit. The US faces compounding weaknesses: a botched Iran policy, rising Democratic midterm odds, and strained G7 alliances. China's rare earth dominance — 70% of global mining, 90%+ of processing — gives Beijing direct leverage over US weapons manufacturing supply chains.
•SCO as Counter-Western Bloc: Track the Shanghai Cooperation Organization as a concrete measure of China's alternative global order. The 10-member bloc covers 42% of world population, 36% of GDP by purchasing power parity, and $523 billion in internal trade. It is establishing its own development bank explicitly designed to shield members from Western financial sanctions.
•China Pharma Out-Licensing Surge: Monitor Chinese pharmaceutical out-licensing deals as a leading indicator of global drug innovation shifts. Deals above $50 million grew from 5% of global share in 2021 to 30% in 2025, reaching 42% in the first half of 2026 alone. AstraZeneca's $18.5 billion deal with CSPC in March 2026 represents the largest single transaction to date.
•Drug Development Cost and Speed Advantage: Factor in China's 30–50% cost reduction and 30–60% faster development timelines when evaluating pharmaceutical partnerships. AI-native companies like In Silico Medicine report 70% reductions in discovery time and evaluated only 78 drug candidates versus the industry norm of thousands, signaling structural efficiency gains beyond simple labor arbitrage.
•STAR Market Growth Trajectory: Watch China's STAR Market — currently 600 companies at $2.3 trillion combined market cap, skewed toward semiconductors, AI, and robotics — as the primary venue for next-generation Chinese tech listings. Domestic listing incentives are replacing New York and Hong Kong preferences, with the STAR Market potentially surpassing Hong Kong's $6.25 trillion market cap within a decade.

Notable Moment

Guest Ruby Wong reveals that Chinese biotech out-licensing deals above $50 million jumped from 5% of global share to 42% in roughly five years — a pace so rapid that multinational pharmaceutical companies are now acquiring not just drug assets but entire Chinese biotech talent teams to replicate their speed and cost efficiencies.

Know someone who'd find this useful?

Episode Transcript

Support for this podcast comes from Juro. What if your business had someone who could draft, negotiate, and manage contracts all while never sleeping, eating, or taking a day off? With AI, it's possible. And with Juro, it's a reality. Juro is the complete solution for business contracting from draft to signature and beyond. Juro gives you conversational access to your contracts and data, plus the connected workflows and integrations you won't find in basic AI review tools. Juro has powered 3,000,000 contracts for a fraction of the cost of hiring a lawyer. Visit juro.com/vox for 20% off year one. Hey. I've got the campaign brief ready built from last quarter's data and the competitive landscape. Approved. Oh, agents. Where would we be without you? Somewhere with a lot more tabs open. Create your first Monday agent in minutes at monday.com. When you need to build up your team to handle the growing chaos at work, use Indeed Sponsored Jobs. It gives your job post the boost it needs to be seen and helps reach people with the right skills, certifications, and more. Spend less time searching and more time actually interviewing candidates who check all your boxes. Listeners of this show will get a $75 sponsored job credit at indeed.com/podcast. That's indeed.com/podcast. Terms and conditions apply. Need a hiring hero? This is a job for Indeed sponsored jobs. The numbers of US dependence on China are startling. You know, China has 50% of the world's API advanced pharmaceutical inputs capacity globally, but, you know, around about half of The US's APIs imported come from China. And that's continuing. I think there is competition from India and from other countries too, but China remains a core global, you know, source of basic, drug, building blocks. Welcome to China Decode. I'm Alice Han. And I'm James King. In today's episode of China Decode, we're discussing the future of US China competition as another Trump Xi meeting approaches, the booming Chinese pharma industry, and what that means for the rest of the globe. Alright. Let's get into it. James, an undercurrent in so many of the stories we do is the ongoing competition between The US and China and what that means for global power that cuts across geopolitical and economic lines, and every lobby back and forth between these two superpowers has impacts. Trump and Xi Jinping will meet next in Washington DC on September 24, a reciprocal visit for Trump's trip to China this past spring. And the conversation is likely to focus on trade and artificial intelligence as well as other economic and political issues, but a lot can shift in just a few weeks. So, James, you know, we've got a major trip coming up on the part of Xi Jinping going to The US. There has been very little in the media that's been leaked about what they're actually going to come out with in terms of deals, so I'm skeptical we get any major announcements. But …

Get the full transcript (7,956 words) + summary by email — free

One-time email with the complete transcript and AI summary of this episode. No account needed.

One email, no spam. We’ll also show you what SignalCast does.

Browse all The Prof G Pod transcripts →